Marrow failure: A window into ribosome biology

Blood

Volumn 124, Issue 18, 2014, Pages 2784-2792

  Ruggero, Davide ^a   Shimamura, Akiko ^b,c,d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

^c SEATTLE CHILDREN S HOSPITAL   (United States)

^d UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DYSKERIN; MAMMALIAN TARGET OF RAPAMYCIN; PROTEIN P53; RIBOSOME PROTEIN;

BIOGENESIS; BLACKFAN DIAMOND ANEMIA; BONE MARROW DEPRESSION; CLINICAL FEATURE; CYTOLOGY; DEVELOPMENTAL BIOLOGY; DYSKERATOSIS CONGENITA; GENE MUTATION; GENETICS; GENODERMATOSIS; HAPLOINSUFFICIENCY; HUMAN; MOLECULAR PATHOLOGY; PROTEIN MODIFICATION; PROTEIN SYNTHESIS; REVIEW; RIBOSOME; SHWACHMAN SYNDROME; SIGNAL TRANSDUCTION; ANIMAL; BIOLOGICAL MODEL; BONE MARROW; BONE MARROW DISEASE; METABOLISM; PATHOLOGY;

ANIMALS; BONE MARROW; BONE MARROW DISEASES; HUMANS; MODELS, BIOLOGICAL; PROTEIN BIOSYNTHESIS; RIBOSOMES;

EID: 84908577172     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2014-04-526301     Document Type: Review

References (128)

1. Shimamura A, Alter BP Pathophysiology and management of inherited bone marrow failure syndromes. Blood Rev. 2010; 24(3): 101-122.
2. Fatica A, Tollervey D. Making ribosomes. Curr Opin Cell Biol. 2002; 14(3):313-318.
3. Vlachos A, Ball S, Dahl N., et al; Participants of Sixth Annual Daniella Maria Arturi International Consensus Conference. Diagnosing and treating Diamond Blackfan anaemia: results of an international clinical consensus conference. Br J Haematol. 2008; 142(6):859-876.
4. Lipton JM, Ellis SR Diamond-Blackfan anemia: diagnosis, treatment, and molecular pathogenesis. Hematol Oncol Clin North Am. 2009; 23(2): 261-282.
5. Da Costa L., Chanoz-Poulard G, Simansour M., et al. First de novo mutation in RPS19 gene as the cause of hydrops fetalis in Diamond-Blackfan anemia. Am J Hematol. 2013; 88(4):340-341.
6. Nathan DG, Clarke BJ, Hillman D.G., Alter BP, Housman DE. Erythroid precursors in congenital hypoplastic (Diamond-Blackfan) anemia. J Clin Invest. 1978; 61(2):489-498.
7. Glader BE, Backer K, Diamond LK Elevated erythrocyte adenosine deaminase activity in congenital hypoplastic anemia. N Engl J Med. 1983; 309(24):1486-1490.
8. Fargo JH, Kratz CP, Giri N, et al Erythrocyte adenosine deaminase: diagnostic value for Diamond-Blackfan anaemia. Br J Haematol. 2013; 160(4):547-554.
9. Vlachos A, Rosenberg PS, Atsidaftos E, Alter B.P., Lipton JM. Incidence of neoplasia in Diamond Blackfan anemia: A report from the Diamond Blackfan anemia registry. Blood. 2012; 119(16):3815-3819.
10. Vlachos A, Muir E. How I treat DiamondBlackfan anemia. Blood. 2010; 116(19): 3715-3723.
11. Narla A, Dutt S, McAuley J.R., et al. Dexamethasone and lenalidomide have distinct functional effects on erythropoiesis. Blood. 2011; 118(8):2296-2304.
12. Vlachos A, Dahl N, Dianzani I., Lipton JM. Clinical utility gene card for: Diamond-Blackfan anemia - update 2013. Eur J Hum Genet. 2013; 21(10).
13. Quarello P, Garelli E, Brusco A., et al. High frequency of ribosomal protein gene deletions in Italian Diamond-Blackfan anemia patients detected by multiplex ligation-dependent probe amplification assay. Haematologica. 2012; 97(12):1813-1817.
14. Sankaran VG, Ghazvinian R, Do R., et al. Exome sequencing identifies GATA1 mutations resulting in Diamond-Blackfan anemia. J Clin Invest. 2012; 122(7):2439-2443.
15. Devlin EE, Dacosta L, Mohandas N., Elliott G, Bodine DM. A transgenic mouse model demonstrates a dominant negative effect of a point mutation in the RPS19 gene associated with Diamond-Blackfan anemia. Blood. 2010; 116(15):2826-2835.
16. Léger-Silvestre I., Caffrey JM, Dawaliby R, et al Specific role for yeast homologs of the Diamond Blackfan anemia-associated Rps19 protein in ribosome synthesis. J Biol Chem. 2005; 280(46): 38177-38185.
17. Choesmel V, Bacqueville D, Rouquette J., et al. Impaired ribosome biogenesis in DiamondBlackfan anemia. Blood. 2007; 109(3): 1275-1283.
18. Flygare J, Aspesi A, Bailey J.C., et al. Human RPS19, the gene mutated in Diamond-Blackfan anemia, encodes a ribosomal protein required for the maturation of 40S ribosomal subunits. Blood. 2007; 109(3):980-986.
19. Robledo S, Idol RA, Crimmins D.L., Ladenson JH, Mason PJ, Bessler M. The role of human ribosomal proteins in the maturation of rRNA and ribosome production. RNA. 2008; 14(9): 1918-1929.
20. Garçon L., Ge J, Manjunath S.H., et al. Ribosomal and hematopoietic defects in induced pluripotent stem cells derived from Diamond Blackfan anemia patients. Blood. 2013; 122(6):912-921.
21. McGowan KA, Mason PJ Animal models of Diamond Blackfan anemia. Semin Hematol. 2011; 48(2):106-116.
22. Al-Rahawan M.M., Alter BP, Bryant B.J., Elghetany MT. Bone marrow cell cycle markers in inherited bone marrow failure syndromes. Leuk Res. 2008; 32(12):1793-1799.
23. Dutt S, Narla A, Lin K., et al. Haploinsufficiency for ribosomal protein genes causes selective activation of p53 in human erythroid progenitor cells. Blood. 2011; 117(9):2567-2576.
24. Ellis SR, Lipton JM Diamond Blackfan anemia: a disorder of red blood cell development. Curr Top Dev Biol. 2008; 82:217-241.
25. Zhang Y, Lu H. Signaling to p53: ribosomal proteins find their way. Cancer Cell. 2009; 16(5): 369-377.
26. Zhou X, Hao Q, Liao J., Zhang Q, Lu H. Ribosomal protein S14 unties the MDM2-p53 loop upon ribosomal stress. Oncogene. 2013; 32(3):388-396.
27. Macias E, Jin A, Deisenroth C., et al. An ARF-independent c-MYC-activated tumor suppression pathway mediated by ribosomal protein-Mdm2 Interaction. Cancer Cell. 2010; 18(3):231-243.
28. Ruggero D. Revisiting the nucleolus: from marker to dynamic integrator of cancer signaling. Sci Signal. 2012; 5(241):pe38.
29. Donati G, Peddigari S, Mercer C.A., Thomas G. 5S ribosomal RNA is an essential component of a nascent ribosomal precursor complex that regulates the Hdm2-p53 checkpoint. Cell Reports. 2013; 4(1):87-98.
30. Fumagalli S, Ivanenkov VV, Teng T, Thomas G. Suprainduction of p53 by disruption of 40S and 60S ribosome biogenesis leads to the activation of a novel G2/M checkpoint. Genes Dev. 2012; 26(10):1028-1040.
31. Bursać S, Brdovčak MC, Pfannkuchen M, et al. Mutual protection of ribosomal proteins L5 and L11 from degradation is essential for p53 activation upon ribosomal biogenesis stress. Proc Natl Acad Sci USA. 2012; 109(50): 20467-20472.
32. Gazda HT, Sheen MR, Vlachos A, et al Ribosomal protein L5 and L11 mutations are associated with cleft palate and abnormal thumbs in Diamond-Blackfan anemia patients. Am J Hum Genet. 2008; 83(6):769-780.
33. Teng T, Mercer CA, Hexley P, Thomas G., Fumagalli S. Loss of tumor suppressor RPL5/RPL11 does not induce cell cycle arrest but impedes proliferation due to reduced ribosome content and translation capacity. Mol Cell Biol. 2013; 33(23):4660-4671.
34. Singh SA, Goldberg TA, Henson A.L., et al. p53-Independent cell cycle and erythroid differentiation defects in murine embryonic stem cells haploinsufficient for Diamond Blackfan anemia-proteins: RPS19 versus RPL5. PLoS ONE. 2014; 9(2):e89098.
35. Taylor AM, Zon LI Modeling Diamond Blackfan anemia in the zebrafish. Semin Hematol. 2011; 48(2):81-88.
36. Liu TX, Howlett NG, Deng M, et al Knockdown of zebrafish Fancd2 causes developmental abnormalities via p53-dependent apoptosis. Dev Cell. 2003; 5(6):903-914.
37. Ceccaldi R, Parmar K, Mouly E., et al. Bone marrow failure in Fanconi anemia is triggered by an exacerbated p53/p21 DNA damage response that impairs hematopoietic stem and progenitor cells. Cell Stem Cell. 2012; 11(1):36-49.
38. Cmejlova J, Dolezalova L, Pospisilova D., Petrtylova K, Petrak J, Cmejla R. Translational efficiency in patients with Diamond-Blackfan anemia. Haematologica. 2006; 91(11): 1456-1464.
39. Fumagalli S, Di Cara A, Neb-Gulati A, et al. Absence of nucleolar disruption after impairment of 40S ribosome biogenesis reveals an rpL11-translation-dependent mechanism of p53 induction. Nat Cell Biol. 2009; 11(4):501-508.
40. Pereboom TC, Bondt A, Pallaki P., et al. Translation of branched-chain aminotransferase-1 transcripts is impaired in cells haploinsufficient for ribosomal protein genes. Exp Hematol. 2014; 42(5):394-403.e4
41. Pospisilova D, Cmejlova J, Hak J., Adam T, Cmejla R. Successful treatment of a DiamondBlackfan anemia patient with amino acid leucine. Haematologica. 2007; 92(5):e66-e67.
42. Jaako P, Debnath S, Olsson K., Bryder D, Flygare J, Karlsson S. Dietary L-leucine improves the anemia in a mouse model for Diamond-Blackfan anemia. Blood. 2012; 120(11):2225-2228.
43. Payne EM, Virgilio M, Narla A., et al. L-Leucine improves the anemia and developmental defects associated with Diamond-Blackfan anemia and del(5q) MDS by activating the mTOR pathway. Blood. 2012; 120(11):2214-2224.
44. Han JM, Jeong SJ, Park M.C., et al. Leucyl-tRNA synthetase is an intracellular leucine sensor for the mTORC1-signaling pathway. Cell. 2012; 149(2):410-424.
45. Boultwood J, Yip BH, Vuppusetty C, Pellagatti A., Wainscoat JS. Activation of the mTOR pathway by the amino acid (L)-leucine in the 5q-syndrome and other ribosomopathies. Adv Biol Regul. 2013; 53(1):8-17.
46. Stipanuk MH. Leucine and protein synthesis: mTOR and beyond. Nutr Rev. 2007; 65(3): 122-129.
47. Boultwood J, Pellagatti A, McKenzie A.N., Wainscoat JS. Advances in the 5q-syndrome. Blood. 2010; 116(26):5803-5811.
48. Ebert BL, Lee MM, Pretz J.L., et al. An RNA interference model of RPS19 deficiency in Diamond-Blackfan anemia recapitulates defective hematopoiesis and rescue by dexamethasone: identification of dexamethasone-responsive genes by microarray. Blood. 2005; 105(12):4620-4626.
49. Barlow JL, Drynan LF, Trim N.L., Erber WN, Warren AJ, McKenzie AN. New insights into 5q-syndrome as a ribosomopathy. Cell Cycle. 2010; 9(21):4286-4293.
50. Vlachos A, Farrar JE, Atsidaftos E, et al Diminutive somatic deletions in the 5q region lead to a phenotype atypical of classical 5q-syndrome. Blood. 2013; 122(14): 2487-2490.
51. Barlow JL, Drynan LF, Hewett D.R., et al. A p53-dependent mechanism underlies macrocytic anemia in a mouse model of human 5q-syndrome. Nat Med. 2010; 16(1):59-66.
52. Dror Y, Donadieu J, Koglmeier J., et al. Draft consensus guidelines for diagnosis and treatment of Shwachman-Diamond syndrome. Ann N Y Acad Sci. 2011; 1242:40-55.
53. Myers KC, Davies SM, Shimamura A. Clinical and molecular pathophysiology of Shwachman-Diamond syndrome: an update. Hematol Oncol Clin North Am. 2013; 27(1):117-128, ix. [ix]
54. Myers KC, Bolyard AA, Otto B, et al Variable clinical presentation of Shwachman-Diamond syndrome: Update from the North American Shwachman-Diamond syndrome registry. J Pediatr. 2014; 164(4):866-870.
55. Stepanovic V, Wessels D, Goldman F.D., Geiger J., Soll DR. The chemotaxis defect of Shwachman-Diamond Syndrome leukocytes. Cell Motil Cytoskeleton. 2004; 57(3):158-174.
56. Orelio C, Kuijpers TW Shwachman-Diamond syndrome neutrophils have altered chemoattractant-induced F-actin polymerization and polarization characteristics. Haematologica. 2009; 94(3):409-413.
57. Grinspan ZM, Pikora CA Infections in patients with Shwachman-Diamond syndrome. Pediatr Infect Dis J. 2005; 24(2):179-181.
58. Rochowski A, Sun C, Glogauer M., Alter BP. Neutrophil functions in patients with inherited bone marrow failure syndromes. Pediatr Blood Cancer. 2011; 57(2):306-309.
59. Dror Y, Ginzberg H, Dalal I., et al. Immune function in patients with Shwachman-Diamond syndrome. Br J Haematol. 2001; 114(3):712-717.
60. Rosenberg PS, Alter BP, Bolyard A.A., et al; Severe Chronic Neutropenia International Registry. The incidence of leukemia and mortality from sepsis in patients with severe congenital neutropenia receiving long-term G-CSF therapy. Blood. 2006; 107(12): 4628-4635.
61. ∗. Classification of and risk factors for hematologic complications in a French national cohort of 102 patients with Shwachman-Diamond syndrome. Haematologica. 2012; 97(9):1312-1319.
62. Sack JE, Kuchnir L, Demierre MF Dermatofibrosarcoma protuberans arising in the context of Shwachman-Diamond syndrome. Pediatr Dermatol. 2011; 28(5):568-569.
63. Dhanraj S, Manji A, Pinto D., et al. Molecular characteristics of a pancreatic adenocarcinoma associated with Shwachman-Diamond syndrome. Pediatr Blood Cancer. 2013; 60(5): 754-760.
64. Nakaya T, Kurata A, Hashimoto H., et al. Young-age-onset pancreatoduodenal carcinoma in Shwachman-Diamond syndrome. Pathol Int. 2014; 64(2):75-80.
65. Singh SA, Vlachos A, Morgenstern N.J., et al. Breast cancer in a case of Shwachman Diamond syndrome. Pediatr Blood Cancer. 2012; 59(5): 945-946.
66. Boocock GR, Morrison JA, Popovic M, et al Mutations in SBDS are associated with Shwachman-Diamond syndrome. Nat Genet. 2003; 33(1):97-101.
67. Rawls AS, Gregory AD, Woloszynek J.R., Liu F., Link DC. Lentiviral-mediated RNAi inhibition of Sbds in murine hematopoietic progenitors impairs their hematopoietic potential. Blood. 2007; 110(7):2414-2422.
68. Sezgin G, Henson AL, Nihrane A, et al Impaired growth, hematopoietic colony formation, and ribosome maturation in human cells depleted of Shwachman-Diamond syndrome protein SBDS. Pediatr Blood Cancer. 2013; 60(2):281-286.
69. Sen S, Wang H, Nghiem C.L., et al. The ribosome-related protein, SBDS, is critical for normal erythropoiesis. Blood. 2011; 118(24): 6407-6417.
70. Tulpule A, Kelley JM, Lensch M.W., et al. Pluripotent stem cell models of Shwachman-Diamond syndrome reveal a common mechanism for pancreatic and hematopoietic dysfunction. Cell Stem Cell. 2013; 12(6):727-736.
71. Zhang S, Shi M, Hui C.C., Rommens JM. Loss of the mouse ortholog of the Shwachman-Diamond syndrome gene (Sbds) results in early embryonic lethality. Mol Cell Biol. 2006; 26(17):6656-6663.
72. Raaijmakers MH, Mukherjee S, Guo S., et al. Bone progenitor dysfunction induces myelodysplasia and secondary leukaemia. Nature. 2010; 464(7290):852-857.
73. Dror Y, Freedman MH Shwachman-Diamond syndrome: An inherited preleukemic bone marrow failure disorder with aberrant hematopoietic progenitors and faulty marrow microenvironment. Blood. 1999; 94(9): 3048-3054.
74. André V, Longoni D, Bresolin S, et al. Mesenchymal stem cells from Shwachman-Diamond syndrome patients display normal functions and do not contribute to hematological defects. Blood Cancer J. 2012; 2:e94.
75. Austin KM, Gupta ML Jr, Coats SA, et al. Mitotic spindle destabilization and genomic instability in Shwachman-Diamond syndrome. J Clin Invest. 2008; 118(4):1511-1518.
76. Orelio C, Verkuijlen P, Geissler J., van den Berg TK, Kuijpers TW. SBDS expression and localization at the mitotic spindle in human myeloid progenitors. PLoS ONE. 2009; 4(9): e7084.
77. Rujkijyanont P, Watanabe K, Ambekar C., et al. SBDS-deficient cells undergo accelerated apoptosis through the Fas-pathway. Haematologica. 2008; 93(3):363-371.
78. Ball HL, Zhang B, Riches J.J., et al. Shwachman-Bodian Diamond syndrome is a multi-functional protein implicated in cellular stress responses. Hum Mol Genet. 2009; 18(19):3684-3695.
79. Leung R, Cuddy K, Wang Y., Rommens J, Glogauer M. Sbds is required for Rac2-mediated monocyte migration and signaling downstream of RANK during osteoclastogenesis. Blood. 2011; 117(6):2044-2053.
80. Henson AL, Moore JB 4th, Alard P, Wattenberg MM, Liu JM, Ellis SR. Mitochondrial function is impaired in yeast and human cellular models of Shwachman Diamond syndrome. Biochem Biophys Res Commun. 2013; 437(1):29-34.
81. Ambekar C, Das B, Yeger H., Dror Y. SBDS-deficiency results in deregulation of reactive oxygen species leading to increased cell death and decreased cell growth. Pediatr Blood Cancer. 2010; 55(6):1138-1144.
82. Menne TF, Goyenechea B, Sánchez-Puig N, et al. The Shwachman-Bodian-Diamond syndrome protein mediates translational activation of ribosomes in yeast. Nat Genet. 2007; 39(4):486-495.
83. Finch AJ, Hilcenko C, Basse N., et al. Uncoupling of GTP hydrolysis from eIF6 release on the ribosome causes Shwachman-Diamond syndrome. Genes Dev. 2011; 25(9):917-929.
84. Wong CC, Traynor D, Basse N., Kay RR, Warren AJ. Defective ribosome assembly in Shwachman-Diamond syndrome. Blood. 2011; 118(16):4305-4312.
85. Ganapathi KA, Austin KM, Lee C.S., et al. The human Shwachman-Diamond syndrome protein, SBDS, associates with ribosomal RNA. Blood. 2007; 110(5):1458-1465.
86. Basu U, Si K, Warner J.R., Maitra U. The Saccharomyces cerevisiae TIF6 gene encoding translation initiation factor 6 is required for 60S ribosomal subunit biogenesis. Mol Cell Biol. 2001; 21(5):1453-1462.
87. Senger B, Lafontaine DL, Graindorge J.S., et al. The nucle(ol)ar Tif6p and Efl1p are required for a late cytoplasmic step of ribosome synthesis. Mol Cell. 2001; 8(6):1363-1373.
88. Ceci M, Gaviraghi C, Gorrini C., et al. Release of eIF6 (p27BBP) from the 60S subunit allows 80S ribosome assembly. Nature. 2003; 426(6966): 579-584.
89. Gartmann M, Blau M, Armache J.P., Mielke T., Topf M, Beckmann R. Mechanism of eIF6-mediated inhibition of ribosomal subunit joining. J Biol Chem. 2010; 285(20):14848-14851.
90. Lo KY, Li Z, Bussiere C., Bresson S, Marcotte EM, Johnson AW Defining the pathway of cytoplasmic maturation of the 60S ribosomal subunit. Mol Cell. 2010; 39(2):196-208.
91. Burwick N, Coats SA, Nakamura T, Shimamura A. Impaired ribosomal subunit association in Shwachman-Diamond syndrome. Blood. 2012; 120(26):5143-5152.
92. Gijsbers A, García-Márquez A, Luviano A, Sánchez-Puig N. Guanine nucleotide exchange in the ribosomal GTPase EFL1 is modulated by the protein mutated in the Shwachman-Diamond syndrome. Biochem Biophys Res Commun. 2013; 437(3):349-354.
93. Asano N, Atsuumi H, Nakamura A., Tanaka Y, Tanaka I, Yao M. Direct interaction between EFL1 and SBDS is mediated by an intrinsically disordered insertion domain. Biochem Biophys Res Commun. 2014; 443(4):1251-1256.
94. De Keersmaecker K., Atak ZK, Li N, et al Exome sequencing identifies mutation in CNOT3 and ribosomal genes RPL5 and RPL10 in T-cell acute lymphoblastic leukemia. Nat Genet. 2013; 45(2):186-190.
95. Hesling C, Oliveira CC, Castilho B.A., Zanchin NI. The Shwachman-Bodian-Diamond syndrome associated protein interacts with HsNip7 and its down-regulation affects gene expression at the transcriptional and translational levels. Exp Cell Res. 2007; 313(20):4180-4195.
96. Martín-Marcos P., Hinnebusch AG, Tamame M. Ribosomal protein L33 is required for ribosome biogenesis, subunit joining, and repression of GCN4 translation. Mol Cell Biol. 2007; 27(17): 5968-5985.
97. Ballew BJ, Savage SA Updates on the biology and management of dyskeratosis congenita and related telomere biology disorders. Expert Rev Hematol. 2013; 6(3):327-337.
98. Dokal I. Dyskeratosis congenita in all its forms. Br J Haematol. 2000; 110(4):768-779.
99. Alter BP, Giri N, Savage S.A., Rosenberg PS. Cancer in dyskeratosis congenita. Blood. 2009; 113(26):6549-6557.
100. Calado RT, Yewdell WT, Wilkerson K.L., et al. Sex hormones, acting on the TERT gene, increase telomerase activity in human primary hematopoietic cells. Blood. 2009; 114(11): 2236-2243.
101. Nourbakhsh M, Golestani A, Zahrai M., Modarressi MH, Malekpour Z, Karami-Tehrani F. Androgens stimulate telomerase expression, activity and phosphorylation in ovarian adenocarcinoma cells. Mol Cell Endocrinol. 2010; 330(1-2):10-16.
102. Ziegler P, Schrezenmeier H, Akkad J., et al. Telomere elongation and clinical response to androgen treatment in a patient with aplastic anemia and a heterozygous hTERT gene mutation. Ann Hematol. 2012; 91(7):1115-1120.
103. Gadalla SM, Sales-Bonfim C, Carreras J., et al. Outcomes of allogeneic hematopoietic cell transplantation in patients with dyskeratosis congenita. Biol Blood Marrow Transplant. 2013; 19(8):1238-1243.
104. Kirwan M, Dokal I. Dyskeratosis congenita: a genetic disorder of many faces. Clin Genet. 2008; 73(2):103-112.
105. Mitchell JR, Wood E, Collins K. A telomerase component is defective in the human disease dyskeratosis congenita. Nature. 1999; 402(6761):551-555.
106. Ruggero D, Grisendi S, Piazza F., et al. Dyskeratosis congenita and cancer in mice deficient in ribosomal RNA modification. Science. 2003; 299(5604):259-262.
107. Kiss T, Fayet-Lebaron E, Jády BE. Box H/ACA small ribonucleoproteins. Mol Cell. 2010; 37(5): 597-606.
108. Meier UT. The many facets of H/ACA ribonucleoproteins. Chromosoma. 2005; 114(1): 1-14.
109. Vulliamy T, Marrone A, Goldman F., et al. The RNA component of telomerase is mutated in autosomal dominant dyskeratosis congenita. Nature. 2001; 413(6854):432-435.
110. Alter BP, Baerlocher GM, Savage S.A., et al. Very short telomere length by flow fluorescence in situ hybridization identifies patients with dyskeratosis congenita. Blood. 2007; 110(5): 1439-1447.
111. Matera AG, Terns RM, Terns MP Non-coding RNAs: lessons from the small nuclear and small nucleolar RNAs. Nat Rev Mol Cell Biol. 2007; 8(3):209-220.
112. Terns M, Terns R. Noncoding RNAs of the H/ACA family. Cold Spring Harb Symp Quant Biol. 2006; 71:395-405.
113. Heiss NS, Knight SW, Vulliamy T.J., et al. X-linked dyskeratosis congenita is caused by mutations in a highly conserved gene with putative nucleolar functions. Nat Genet. 1998; 19(1):32-38.
114. Knight SW, Heiss NS, Vulliamy T.J., et al. Unexplained aplastic anaemia, immunodeficiency, and cerebellar hypoplasia (Hoyeraal-Hreidarsson syndrome) due to mutations in the dyskeratosis congenita gene, DKC1. Br J Haematol. 1999; 107(2):335-339.
115. Gu BW, Bessler M, Mason PJ A pathogenic dyskerin mutation impairs proliferation and activates a DNA damage response independent of telomere length in mice. Proc Natl Acad Sci USA. 2008; 105(29):10173-10178.
116. Lafontaine DLJ, Bousquet-Antonelli C, Henry Y., Caizergues-Ferrer M, Tollervey D. The box H 1 ACA snoRNAs carry Cbf5p, the putative rRNA pseudouridine synthase. Genes Dev. 1998; 12(4):527-537.
117. Zebarjadian Y, King T, Fournier M.J., Clarke L., Carbon J. Point mutations in yeast CBF5 can abolish in vivo pseudouridylation of rRNA. Mol Cell Biol. 1999; 19(11):7461-7472.
118. Ni J, Tien AL, Fournier MJ Small nucleolar RNAs direct site-specific synthesis of pseudouridine in ribosomal RNA. Cell. 1997; 89(4):565-573.
119. Bellodi C, McMahon M, Contreras A., et al. H/ACA small RNA dysfunctions in disease reveal key roles for noncoding RNA modifications in hematopoietic stem cell differentiation. Cell Reports. 2013; 3(5): 1493-1502.
120. Jack K, Bellodi C, Landry D.M., et al. rRNA pseudouridylation defects affect ribosomal ligand binding and translational fidelity from yeast to human cells. Mol Cell. 2011; 44(4): 660-666.
121. Yoon A, Peng G, Brandenburger Y., et al. Impaired control of IRES-mediated translation in X-linked dyskeratosis congenita. Science. 2006; 312(5775):902-906.
122. Bellodi C, Kopmar N, Ruggero D. Deregulation of oncogene-induced senescence and p53 translational control in X-linked dyskeratosis congenita. EMBO J. 2010; 29(11):1865-1876.
123. Noller HF, Hoffarth V, Zimniak L. Unusual resistance of peptidyl transferase to protein extraction procedures. Science. 1992; 256(5062):1416-1419.
124. Xue S, Barna M. Specialized ribosomes: a new frontier in gene regulation and organismal biology. Nat Rev Mol Cell Biol. 2012; 13(6):355-369.
125. Decatur WA, Fournier MJ rRNA modifications and ribosome function. Trends Biochem Sci. 2002; 27(7):344-351.
126. Warner JR, McIntosh KB How common are extraribosomal functions of ribosomal proteins? Mol Cell. 2009; 34(1):3-11.
127. Zhang Y, Duc AC, Rao S, et al Control of hematopoietic stem cell emergence by antagonistic functions of ribosomal protein paralogs. Dev Cell. 2013; 24(4):411-425.
128. Kondrashov N, Pusic A, Stumpf C.R., et al. Ribosome-mediated specificity in Hox mRNA translation and vertebrate tissue patterning. Cell. 2011; 145(3):383-397.